Nanwei medical: 49 institutions went to investigate overseas income more than 40percent and return on net assets declined

category:Finance
 Nanwei medical: 49 institutions went to investigate overseas income more than 40percent and return on net assets declined


According to its performance, in the first half of 2020, the net profit of Nanwei Medical Co., Ltd. fell into negative growth. Its operating income was 570 million yuan, a year-on-year decrease of 7.64%, and the net profit was 114 million yuan, a year-on-year decrease of 24.19%. And in recent years, its return on net assets has declined. In addition, due to the epidemic situation, Latin America, the Middle East, Asia Pacific and other regional markets recovered relatively slowly. On the whole, the recovery of the international market was uneven and was still in the climbing period.

1u3001 According to the survey of 49 institutions, 19 fund companies now have overseas income of more than 40%, and roe has declined

On October 13, Nanwei Medical Co., Ltd. announced its acceptance of the institutional research on September 1. Gong Xingliang, the Secretary of the board of directors, and Tang Ni, the securities affairs representative, received a total of 49 institutions research. Among them, 19 fund management companies, including Huaxia Fund, Guangfa fund and Penghua Fund, and 6 securities companies, including Everbright Securities, CITIC Securities and Guosheng securities, conducted research on them.

The closing price of Nanwei Medical Co., Ltd. was 222.87 yuan / share on the day of institutional research, that is, on September 1, compared with 234 yuan / share on October 14, 230.5 yuan / share on October 15, 222.9 yuan / share on October 16, and 216.2 yuan / share on October 19. As of October 20, the closing price of Nanwei medicine was 211.97 yuan / share.

However, the lowest price of Nanwei Medical Co., Ltd. appeared on April 2, with a share price of 149 yuan / share, and then showed a trend of shock and rise.

(Photo by Oct. 20, 2020)

By sales area classification, over 40% of the revenue of South micro medicine comes from overseas.

In 2017-2019, the income from overseas of Nanwei medical was 286 million yuan, 410 million yuan and 541 million yuan respectively, accounting for 44.77%, 44.7% and 41.52% of the main business income in the same period.

According to Ifind data of tonghuashun, from 2015 to 2019, the operating revenue of Nanwei medical was 261 million yuan, 414 million yuan, 641 million yuan, 922 million yuan and 1.307 billion yuan, respectively, with a year-on-year growth of 58.93%, 54.64%, 43.93% and 41.79% in 2016-2019.

By the first half of 2020, the operating revenue of Nanwei medical is 570 million yuan, with a year-on-year growth of - 7.64%, and the net profit is 114 million yuan, with a year-on-year growth of - 24.19%.

From 2015 to 2019, the net profit of Nanwei medical was 31 million yuan, - 36 million yuan, 101 million yuan, 193 million yuan and 304 million yuan respectively, with a year-on-year increase of - 216.42%, 377.56%, 90.45% and 57.55% in 2016-2019.

From 2015 to 2019, the net cash flow generated by Nanwei medical business activities was RMB 10 million, RMB 80 million, RMB 140 million, RMB 192 million and RMB 252 million respectively.

In the same period, the gross profit margin of Nanwei medical was 48.61%, 57.2%, 60.57%, 63.77% and 65.97%, respectively.

From 2016 to 2019, the weighted average return rates of Nanwei medical after deducting non payment were 19.06%, 26.27%, 32.89% and 19.85%, respectively.

2u3001 The recovery of the international market is uneven, and it is generally in a recovery climbing period

In this institutional survey, executives of Nanwei Medical Co., Ltd. briefly answered five questions concerned by some investors.

In short, in the first half of 2020, due to the epidemic situation, the recovery of regional markets in Latin America, the Middle East, and the Asia Pacific region was relatively slow. On the whole, the recovery of the international market was uneven and was still in the climbing period. The main customers of Nanwei medical in the United States are outpatient operation centers, and the overall recovery situation is better than that of large hospitals. American customers mainly use hemostatic clips, biopsy forceps, EMR / ESD devices and stents, balloons and other products, with a high proportion of basic consumables.

1. Please introduce the recent recovery of the international market.

2. How is the progress of Neurosurgery projects in the companys new layout?

A: the intracranial tunnel distraction surgery system has entered the domestic clinical stage; the Department of brain balloon plans to submit the CFDA registration this year; the visual subdural brain irrigation system plans to submit CFDA registration inspection this year. At present, neurosurgery related projects are progressing smoothly.

3. In the first half of the year, the company has set up several marketing sub centers. What is the positive significance of this to the domestic market development?

A: seven marketing sub centers have been set up in China. Each marketing sub center is equipped with staff for product sales, distribution services, academic promotion, market access and other aspects, which is conducive to improving the service quality of regional terminal customers and better carrying out the promotion of academic sinking. 4. How about the sales situation of disposable high frequency cutter this year? A: the companys disposable high-frequency cutter (Golden knife) has been in good sales since it was listed in April last year. Last year, the domestic sales volume was nearly 10000. This year, the domestic sales volume has maintained a stable growth, and the sales volume in the first half of the year has exceeded that of the whole year last year. The product has obtained the registration certificate in the European Union and the United States, and will be gradually marketed. 5. What is the composition of product revenue of American companies? A: at present, the main customers in the U.S. market are outpatient operation centers, with a high proportion of basic consumables, mainly including hemostatic clips, biopsy forceps, EMR / ESD devices and stents, balloons and other products. Since last year, we began to expand the hospital market with innovative products. Source of this article: Chen Hequn, editor in charge of financial securities research_ NB12679

A: seven marketing sub centers have been set up in China. Each marketing sub center is equipped with staff for product sales, distribution services, academic promotion, market access and other aspects, which is conducive to improving the service quality of regional terminal customers and better carrying out the promotion of academic sinking.

4. How about the sales situation of disposable high frequency cutter this year?

A: the companys disposable high-frequency cutter (Golden knife) has been in good sales since it was listed in April last year. Last year, the domestic sales volume was nearly 10000. This year, the domestic sales volume has maintained a stable growth, and the sales volume in the first half of the year has exceeded that of the whole year last year. The product has obtained the registration certificate in the European Union and the United States, and will be gradually marketed.

A: at present, the main customers in the U.S. market are outpatient operation centers, with a high proportion of basic consumables, mainly including hemostatic clips, biopsy forceps, EMR / ESD devices and stents, balloons and other products. Since last year, we began to expand the hospital market with innovative products.